Author:
Hudson Marie,Tascilar Koray,Suissa Samy
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. US Institute of Medicine Committee on Comparative Effectiveness Research Prioritization. Initial national priorities for comparative effectiveness research. (National Academies Press, 2009).
2. Garber, A. M. & Sox, H. C. The role of costs in comparative effectiveness research. Health Aff. (Millwood) 29, 1805–1811 (2010).
3. Estellat, C. & Ravaud, P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch. Intern. Med. 172, 237–244 (2012).
4. Weinblatt, M. E. et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 65, 28–38 (2013).
5. Gabay, C. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381, 1541–1550 (2013).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献